buserelin

(redirected from Suprefact)

buserelin

A long-acting GnRH-gonadotropin-releasing hormone analogue, which causes permanent pitutary stimulation and downregulates the pituitary-gonadal axis, blocking testosterone production in the testes; it has been used to treat metastatic prostate and breast cancer, to create pseudomenopause to reduce the size and number of endometriotic lesions and fibroids. It has also been used for hirsutism, to induced ovulation and for in vitro fertilisation.

buserelin

Suprefact® Infertility A long-acting gonadotropin-releasing hormone analogue which downregulates the pituitary-gonadal axis, block testosterone production in the testes; it has been used to treat metastatic prostate CA. See Disease flare.

buserelin

A gonadothropin-releasing hormone drug used in the treatment of ENDOMETRIOSIS and INFERTILITY. Brand names are Suprecur and Suprefact.
Mentioned in ?
References in periodicals archive ?
In addition, the brand of LHRH agonist (Lupron [Abbott Laboratories, Saint Laurent,QC], Zoladex [AstraZeneca Canada, Mississauga, ON], Suprefact [sanofi-aventis, Laval, QC], Eligard [sanofi-aventis, Laval, QC], Trelstar [Watson Pharma Inc.
However this tremendous discrepancy in price does not simply include basic pain relief, but also antibiotics such as Dalacin and Augmentin, cancer medication such as Casodex and Suprefact, along with anti-depression medication such as Xanax and Lexotanil, among others.
Scope of Report: - Epidemiology of endometriosis in seven major markets, identifying subpopulations and unmet needs - Detailed profiles of drugs in Phase II and above examining clinical data and benchmarked against gold standard using quantitative SWOT analysis - Country-specific sales forecasts for the seven major markets, based on IMS MIDAS data covering key ATC classes G3A, G3D, G3H, H1C1 (L2A) and H1C3 - Extensive secondary research and utilization of licensed and in-house databases supplemented by primary research interviews with key opinion leaders Report Highlights: The endometriosis market will change dramatically following the patent expiry of key brands Lupron Depot, Zoladex and Suprefact.
Follicles were aspirated under ultrasound-guided transvaginal puncture after pituitary desensitization with Buserilin nasal spray (800 [micro]g daily; Suprefact, Hoechtst, Belgium) followed by human menopausal gonadotropin (hMG), only 2 ampules of 75 U daily until at least two follicles reached a diameter of 20 mm.